Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098399 | 0.87 | LMNA (0.49) | LMNATP53MAPTCYP1A2CYP2C19 | |
| SCHEMBL23361862 | 0.85 | CSF1R (0.57) | PPARGMAPTCYP1A2POLBKMT2A | |
| SCHEMBL4089473 | 0.84 | MAPT (0.63) | LMNATP53MAPTPOLBKMT2A | |
| SCHEMBL4083104 | 0.81 | TP53 (0.54) | PPARGLMNATP53MAPTPOLB | |
| SCHEMBL20715421 | 0.81 | HTR3A (0.53) | MCHR1 | |
| SCHEMBL22726431 | 0.81 | MCHR1 (0.55) | PPARGLMNATP53MAPTCYP1A2 | |
| SCHEMBL20715420 | 0.80 | HTR3A (0.52) | MCHR1 | |
| SCHEMBL31633144 | 0.79 | TSHR (0.66) | LMNATP53MAPTPOLBALOX5AP | |
| SCHEMBL4083319 | 0.79 | TP53 (0.63) | LMNATP53MAPTCYP2C19KMT2A | |
| SCHEMBL1169953 | 0.78 | LMNA (0.70) | LMNATP53MAPTCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| EP-1778670-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM Pharma A/S (DK) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010446-A2 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | PPARG 407/4885LMNA 2850/4885TP53 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.